Bartosz Hudzik: Extended Anticoagulation in Cancer-Associated VTE – Who Is at Higher Bleeding Risk?
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn about a recent article by Isabelle Mahé et al, published in The Lancet Haematology:
”Extended anticoagulation in cancer-associated VTE: who is at higher bleeding risk?
Extended anticoagulation with reduced-dose apixaban has been shown to be non-inferior to full-dose therapy for preventing recurrent VTE in patients with active cancer—while offering fewer clinically relevant bleeding events.
A new post-hoc analysis of the API-CAT trial takes a closer look at predictors of clinically relevant bleeding during extended therapy.
Key findings (12-month follow-up, n=1,766):
Four factors were independently associated with increased bleeding risk:
• Anaemia and/or thrombocytopenia
• Age ≥75 years
• Pulmonary embolism as the index event
• Male sex
Notably:
• Results were consistent across cancer types
• No interaction with apixaban dose was observed
Why this matters
Although API-CAT was not designed to guide anticoagulation discontinuation, these insights may help clinicians better individualize extended anticoagulation, balancing thrombotic protection against bleeding risk in patients with cancer-associated VTE.”
Title: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti for the API-CAT Study Group and API-CAT Investigators
Read the Full Article on The Lancet Haematology
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 21, 2026, 20:56George Touma: ApoB Should Be Central to All Lipid Guidlines
-
Sep 21, 2026, 20:55Christopher Robinson: Obstetric Risks Are Seen at the Extremes of Birthweight
-
Sep 21, 2026, 20:54Emicizumab for Refractory GI Bleeding in Myeloma-Associated Acquired VWD – JTH
-
Sep 21, 2026, 20:52Ross Baker: ASH 2026 Guidelines on Iron Deficiency in HMB and Bleeding Disorders
-
Sep 21, 2026, 20:50Rainer Kaiser: Genes and Signalling Pathways Implicated in Procoagulant Platelet Generation
-
Sep 21, 2026, 20:49Natalia Dovlatova: Celebrating Stan Heptinstall and His Legacy in Platelet Science
-
Sep 21, 2026, 20:48Norm Roulet: The Interaction of Pb and SARS-CoV-2 and Its Impact on the Cardiovascular System
-
Sep 21, 2026, 20:45Felix Scholkmann: The Spleen Plays a Key Role in Regulating Platelet Activity
-
Sep 21, 2026, 20:43Claire Pomeroy: Celebrating the 2026 Lasker Awards and Why Medical Research Matters